Navigation Links
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

rials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody MT103 is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. The second clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody which targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The third clinical stage antibody, MT293 is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding the efficacy, safety, and intended utilization of Micromet's product candidate
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... , ... VetStem Biopharma will be offering weekly private guided tours of our ... , The tour and course will be given every Wednesday at 6pm to local ... Staff members are welcome to attend with their veterinarian as well. Participants will be ...
(Date:7/28/2015)... -- Deerfield Management Company, L.P. today announced the launch ... invest in groundbreaking advancements in science that may lead ... diseases. The venture capital fund will also back new ... improve the way healthcare is delivered to patients. ... funds in the sector, will donate all profits not ...
(Date:7/28/2015)... 2015 Tauriga Sciences, Inc. (OTCQB:  TAUG) or ... today announced that its stockholders approved an increase in ... the Company from 1,000,000,000 to 2,500,000,000 at its Special ... the Law Offices of Nixon Peabody LLP in Midtown ... were 480,655,929 shares of common stock represented either by ...
(Date:7/28/2015)... SAN DIEGO , July 28, 2015  Kerastem ... conditional approval from the U.S. FDA Center For Biologics ... Gene Therapies to conduct a clinical trial investigating the ... treatment of female and early male pattern baldness (androgenic ... the STYLE trial, follows initial clinical work in ...
Breaking Biology Technology:VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2
... /Xinhua-PRNewswire-FirstCall/ -- Yongye Biotechnology,International, Inc. (OTC Bulletin Board: ... and distributor of nutrients for plants and,animals in ... it will,conduct a conference call at 8:00 a.m. ... results for the quarter ended June 30, 2008., ...
... ethanol in Scotland, S.D. to start in Q4 ,08. , ... ... the American Coalition for Ethanol conference, http://www.poet.com [POET] announced ... ethanol production facility later this year. The pilot plant will be ...
... 40.8% to $11.6 million ... Net Income increased 118.8% to $2.5 million, ... Medicine,Corporation (OTC Bulletin Board: CHME) ("China Medicine" or ... and over-the-counter,pharmaceuticals, traditional Chinese medicines ("TCM"), nutritional and,dietary-supplements, ...
Cached Biology Technology:Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results 2POET Announces That Cellulosic Ethanol Pilot Facility Will Be Operational This Year 2POET Announces That Cellulosic Ethanol Pilot Facility Will Be Operational This Year 3China Medicine Announces Strong Second Quarter 2008 Results 2China Medicine Announces Strong Second Quarter 2008 Results 3China Medicine Announces Strong Second Quarter 2008 Results 4China Medicine Announces Strong Second Quarter 2008 Results 5China Medicine Announces Strong Second Quarter 2008 Results 6China Medicine Announces Strong Second Quarter 2008 Results 7China Medicine Announces Strong Second Quarter 2008 Results 8China Medicine Announces Strong Second Quarter 2008 Results 9China Medicine Announces Strong Second Quarter 2008 Results 10China Medicine Announces Strong Second Quarter 2008 Results 11
(Date:7/27/2015)... 27, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Huawei has selected the Synaptics ... its stylish smartwatch. Huawei chose the state-of-the-art ClearPad ... power and highly responsive human interface qualities such ... also required a classic round watch face and ...
(Date:7/27/2015)... , July 27, 2015   Zynx Health ... experience-based clinical improvement solutions, today announced that its ... now available on Android smartphones and tablets. With ... post-care organizations can use ZynxCarebook to securely exchange ... condition, streamline care transitions to other care settings, ...
(Date:7/23/2015)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its second quarter ended June 30, 2015.  ... a decrease of 33% compared to $6.8 million in the ... of 2015 was $0.3 million, or $0.01 per diluted share, ... in the same period a year ago.  ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... to migrate to the appropriate locations in the brain and ... in an intricate network. Growth cones, structures in the tips ... right direction, guided by a complex set of signals from ... axons to extend and grow in a particular direction; others ...
... unlocked the molecular give and take that allows cells ... a jigsaw-like pattern, providing the leaf a surprising degree ... of the journal Cell. , Zhenbiao Yang, a professor ... Plant Cell Biology and Institute for Integrative Genome Biology, ...
... how a suspect version of a gene may slightly increase ... by the National Institutes of Health's (NIH) National Institute of ... of activity linked to production of a key brain messenger ... front of the brain predicted increases in the neurotransmitter dopamine ...
Cached Biology News:Cerebral navigation: How do nerve fibers know what direction to grow in? 2Brain Scans Reveal How Gene May Boost Schizophrenia Risk 2Brain Scans Reveal How Gene May Boost Schizophrenia Risk 3
... mid-, near- and far-infrared range FT-IR spectrometers ... in their class. Yet all this comes ... Highest-energy throughput: Having a larger and ... to other conventional FT-IRs provides 300%,larger solid ...
... The CEQ 8800 Genetic Analysis System, ... samples. This automated system adds a higher ... The CEQ 8800, part of Beckman Coulters ... bar coding link with the Biomek series liquid ...
... were designed for full-length gene cloning and ... identify the desired cDNA clone. The first ... "Master Plate," where each well contains plasmid ... positive well(s) by gel electrophoresis of the ...
... Studio Enterprise is integrated informatics solution ... mechanisms and drug response modeling. This ... worlds largest knowledge base of biological ... MedScan module capable of extracting pathway-related ...
Biology Products: